TIPRANAVIR (APTIVUS)

Course overview

Tipranavir (TPV; boosted with ritonavir) is U.S. FDA-approved to treat HIV-1 infections in treatment-experienced patients with HIV strains that are resistant to > 1 protease inhibitor (PI), as part of highly- active antiretroviral therapy (HAART). This continuing education module is designed to give the reader/learner an increased understanding of tipranavir. Readers may explore any or all of the topics. One contact hour of continuing education credit is available for those who successfully complete the post-test and evaluation form.